18:13 , Sep 28, 2018 |  BC Week In Review  |  Company News

Geron shares fall after Janssen discontinues partnership

Janssen Biotech Inc. said it returned exclusive, worldwide development and commercialization rights for imetelstat to Geron Corp. (NASDAQ:GERN). The Johnson & Johnson (NYSE:JNJ) unit said the decision was based on a strategic review of its...
00:01 , Sep 28, 2018 |  BC Extra  |  Company News

Geron shares fall after Janssen returns imetelstat rights

Janssen Biotech Inc. said it returned exclusive, worldwide development and commercialization rights for imetelstat to Geron Corp. (NASDAQ:GERN). The Johnson & Johnson (NYSE:JNJ) unit said the decision was based on a strategic review of its...
20:08 , Jan 19, 2018 |  BC Week In Review  |  Clinical News

Geron reports Phase II data of imetelstat for MDS

Geron Corp. (NASDAQ:GERN) said IV imetelstat (JNJ-63935937, GRN163L) led to a rate of red blood cell (RBC) transfusion-independence for at least eight weeks, the primary endpoint, of 38%. The data were from the first 32...
23:16 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Imetelstat: Additional Ph II IMbark data

Geron said a joint steering committee's second internal review of data from about 100 patients in the open-label, international Phase II IMbark trial "suggest a potential overall survival benefit" for 9.4 mg/kg IV imetelstat dosed...
15:47 , Apr 13, 2017 |  BC Week In Review  |  Clinical News

Imetelstat: Additional Ph II/III IMerge data

Geron said based on second internal review of data from about 30 patients in the Phase II portion, a joint steering committee recommended continuation of the international Phase II/III IMerge trial evaluating IV imetelstat at...
20:17 , Apr 10, 2017 |  BC Extra  |  Company News

Geron gains as imetelstat studies proceed

Geron Corp. (NASDAQ:GERN) gained $0.42 (20%) to $2.57 after it said two studies of imetelstat ( GRN163L ) to treat myelofibrosis (MF) and myelodysplastic syndrome (MDS) will continue without modifications. The company said its partner,...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Imetelstat: Interim Phase II data

Geron said the activity observed in the 4.7 mg/kg imetelstat arm does not warrant further investigation of the dose following an interim review of 12-week data from 40 patients with intermediate-2 or high-risk myelofibrosis who...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

Imetelstat: Interim Phase II/III data

Interim data from the open-label first part of the 2-part, international Phase II/III IMerge trial in patients with low or intermediate-1 risk MDS that is relapsed or refractory to ESAs showed that the safety and...
07:00 , Sep 12, 2016 |  BC Extra  |  Clinical News

Geron falls on imetelstat update

Geron Corp. (NASDAQ:GERN) sank $0.56 (20%) to $2.30 on Monday after reporting that partner Janssen Biotech Inc. will close the low-dose arm of the Phase II IMbark study of imetelstat ( GRN163L ) to treat...